Sanuwave Health (SNWV) to Release Quarterly Earnings on Tuesday
by Scott Moore · The Cerbat GemSanuwave Health (NASDAQ:SNWV – Get Free Report) will likely be issuing its Q4 2025 resultson Tuesday, April 7th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $13.25 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:30 AM ET.
Sanuwave Health (NASDAQ:SNWV – Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.14). Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The company had revenue of $13.09 million during the quarter, compared to analyst estimates of $13.23 million.
Sanuwave Health Stock Performance
Shares of NASDAQ SNWV opened at $16.90 on Monday. Sanuwave Health has a 1-year low of $16.27 and a 1-year high of $46.58. The company has a 50-day moving average of $23.01 and a two-hundred day moving average of $28.68. The company has a market cap of $145.17 million, a PE ratio of -105.62 and a beta of 1.51. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 10.08.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Zacks Research lowered shares of Sanuwave Health from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Roth Mkm reiterated a “buy” rating and issued a $47.00 price objective (down from $53.00) on shares of Sanuwave Health in a research report on Monday, March 30th. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings upgraded Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.
View Our Latest Report on SNWV
Hedge Funds Weigh In On Sanuwave Health
Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in Sanuwave Health during the 1st quarter worth $337,000. Geode Capital Management LLC acquired a new position in shares of Sanuwave Health in the 2nd quarter valued at $5,184,000. JPMorgan Chase & Co. bought a new position in shares of Sanuwave Health in the 2nd quarter worth $109,000. Legal & General Group Plc bought a new position in shares of Sanuwave Health in the 2nd quarter worth $26,000. Finally, Rhumbline Advisers acquired a new stake in shares of Sanuwave Health during the second quarter worth $211,000. 42.53% of the stock is owned by institutional investors.
About Sanuwave Health
Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.
The company’s lead product, the dermaPACE® system, holds clearance from the U.S.